AMGN · News · 20260911N
IMDELLTRA Pipeline Progress
AMGEN INC · 2026-09-11 · Importance 31 · Surprise 42 · In source text
Amgen’s IMDELLTRA showed improved overall survival in a Phase III study for small-cell lung cancer. Amgen is seeking to reduce patient-monitoring requirements, which could improve access and support broader commercialization. The results strengthened the commercial outlook for IMDELLTRA and its combination with AstraZeneca’s IMFINZI, although third-party reporting noted challenges in translating trial success into substantial revenue.
Key facts
- Amgen is seeking to reduce patient monitoring requirements to improve access for IMDELLTRA. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Amgen is seeking to reduce patient monitoring requirements to improve access for IMDELLTRA. |